Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01966627 · ClinicalTrials.gov registry record
Genetics of Fatty Liver Disease in Children
A clinical trial of Non-alcoholic Fatty Liver Disease, sponsored by Yale University.
- Completed
- Registry status
- 381
- Enrollment target
- 1
- Study location
NCT01966627: Completed study of Non-alcoholic Fatty Liver Disease, sponsored by Yale University.
NCT01966627 is a study of Non-alcoholic Fatty Liver Disease that has completed, run by Yale University. The registered enrollment target is 381 participants, above the 171-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (123% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01966627, a study of Non-alcoholic Fatty Liver Disease, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 381 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents. Hypothesis 1: Common variants recently associated with variation in plasma TG levels identified in Genome Wide Association Studies (GWAS) (such as GCKR, PNPLA3) can affect accumulation of fat and subsequent development of Non Alcoholic Fatty Liver Disease (NAFLD). Gene variants act in additive or synergistic manner with progressive liver fat accumulation per additional risk allele. Hypothesis 2: With increase in hepatic fat content NASH and fibrosis will increase. Furthermore, expression of lipogenic markers (SREBP1c) will increase.
Primary Outcome
gene mutation allele variation identification measure via gene extraction
Conditions Studied
Interventions
- OTHER stool sample
- OTHER ogtt
- OTHER genotyping
- OTHER abdominal and liver magnetic resonance imaging
- OTHER liver biopsy
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2011-07 |
| Est. Completion | 2017-07 |
What the finished NCT01966627 record still lists
NCT01966627 is an observational study that tracks outcomes without assigning an intervention. The registered 381 participants enrollment target is mid-sized for trials with a published cap, above the 171-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (123% higher).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 5 interventions - of which stool sample is the first listed.
NCT01966627 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01966627 about?
NCT01966627 is a clinical study titled "Genetics of Fatty Liver Disease in Children". This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents. Hypothesis 1: Common variants recently associated with variation in plasma TG levels identified in Genome Wide Association ...
What is the current status of trial NCT01966627?
This trial is currently completed. The enrollment target is 381 participants. The study started on 2011-07. Estimated completion is 2017-07.
What conditions does trial NCT01966627 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT01966627?
The interventions under investigation include: stool sample (OTHER), ogtt (OTHER), genotyping (OTHER), abdominal and liver magnetic resonance imaging (OTHER), liver biopsy (OTHER).
Who is sponsoring clinical trial NCT01966627?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01966627 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01966627's enrollment target sits among peer trials
381 7th of 57 higher than 51 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RECRUITING · Phase 3
-
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RECRUITING · Phase 3
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RECRUITING
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05677490 · 382 participants · Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- NCT06196008 · 382 participants · NA
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
- NCT07100990 · 382 participants · Phase 3
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia